Related Experiment Video

Updated: May 8, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
09:29

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds

Published on: October 29, 2015

Viral hepatitis: Cost-effectiveness of direct-acting antivirals for chronic hepatitis C

Gaby Sroczynski1, Uwe Siebert

  • 1Department of Public Health and Health Technology Assessment, UMIT (University for Health Sciences, Medical Informatics and Technology), Eduard Wallnoefer Center I, A-6060 Hall in Tirol, Austria.

Nature Reviews. Gastroenterology & Hepatology
|August 21, 2013
PubMed

Insights

Direct-acting antivirals like telaprevir and boceprevir show long-term effectiveness for chronic hepatitis C. These treatments are also cost-effective, informing clinical and reimbursement decisions for high-prevalence populations.

Area of Science:

  • Hepatology
  • Pharmacoeconomics

Background:

  • Chronic hepatitis C (HCV) infection poses a significant global health burden.
  • Direct-acting antivirals (DAAs) represent a major advancement in HCV treatment.
  • Evaluating the long-term outcomes and economic impact of DAAs is crucial for clinical practice and healthcare policy.

Discussion:

  • This study assesses the sustained efficacy and cost-effectiveness of telaprevir and boceprevir for chronic hepatitis C.
  • Long-term data are essential for understanding the durability of treatment response and potential for sustained virologic response.
  • Economic analyses inform resource allocation and reimbursement strategies in healthcare systems.

Key Insights:

  • Telaprevir and boceprevir demonstrate long-term effectiveness in managing chronic hepatitis C.
  • The cost-effectiveness of these DAAs supports their use in clinical decision-making.
  • Findings are particularly relevant for regions with a high prevalence of HCV infection.

Outlook:

  • Continued monitoring of long-term outcomes for current and emerging HCV therapies is warranted.
  • Evidence-based pharmacoeconomic data will guide future treatment guidelines and formulary decisions.
  • Improved access to effective and affordable HCV treatments can reduce the long-term burden of liver disease.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...